T1	Participants 140 201	patients with progressive castrate metastatic prostate cancer
T2	Participants 633 720	Between December 2001 and October 2003, 92 patients were enrolled and randomly assigned
T3	Participants 724 811	treatment with ixabepilone alone (45 patients) or in combination with EMP (47 patients)
#1	AnnotatorNotes T3	2 groups-(45 patients) and(47 patients)
